Molecular researchers from the University of Copenhagen have teamed up with the US-based company Insilico Medicine specialized in artificial intelligence. The hope is to develop new drugs against age-related diseases such as Alzheimer’s, Parkinson’s, and cardiovascular diseases.
BY MIKKEL AABENHUS HEMMINGSEN Offentliggjort 09.08.17 kl. 11:18
Log ind for at læse artikler
Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.
Genmab’s Darzalex royalties now cover the company’s operating costs and in addition to that, the cancer drug continues its expansion to new markets. And according to CEO, Jan van de Winkel, Genmab could potentially raise its guidance this year.
Bioporto’s sales of antibodies and the kidney test NGAL for research use have grown rapidly in 2017. Despite this, the company is forced to downgrade its financial expectations, now expecting a larger deficit for the year. But there is a perfectly good reason for that, explains the CEO.
Zealand Pharma has listed on the Nasdaq Global Select Market in addition to its listing in Copenhagen, raising USD 89 in the process. But the move does not mean the biotech company has lost faith in the Danish investor base, says CEO Britt Meelby Jensen.
Denmark’s ALK is ready to go “full steam” in the launch of a promising tablet against house dust mite allergy on the US market as early as this year. The only obstacle is a formal handover of the marketing permit from former partner Merck, which could push the launch into 2018.
The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.
Den samlede arbejdsstyrke i verdens største medicinalselskaber er blevet holdt nogenlunde i ro mellem 2015 og 2016. Men i de enkelte selskaber, herunder de to største aktører i Danmark, er der stor forskel på, om man hyrer eller fyrer.